<DOC>
	<DOCNO>NCT00458653</DOCNO>
	<brief_summary>The main purpose study test safety determine type severity side effect Dendritic Cell Fusion Vaccine give combination autologous transplant patient multiple myeloma . Autologous stem cell transplantation standard therapy multiple myeloma often successful significantly decrease amount cancer . However , cure point multiple myeloma generally begin grow . Cancer vaccines investigational agent try stimulate immune system recognize fight cancer cell . One type cancer vaccine use immune stimulate cell body know dendritic cell . Research show dendritic cell stimulate immune response tumor .</brief_summary>
	<brief_title>Vaccination With Dendritic Cell/Tumor Fusions With Autologous Stem Cell Transplants Patients With Multiple Myeloma</brief_title>
	<detailed_description>- The first group participant study receive 3 monthly dos study vaccine begin 1 month follow autologous transplant . If find safe , next group receive one additional study vaccine prior transplant 3 dos transplant . - If screening test determine participant eligible study , undergo dendritic cell collection procedure call leukapheresis . Leukapheresis involve collection white blood cell blood . Dendritic cell grown white blood cell laboratory . Tumor cell also collect bone marrow bone marrow aspirate/biopsy . - After cell collect study vaccine generation , participant may receive standard therapy reduce number multiple myeloma cell body . The specific regimen determine participant multiple myeloma physician . - The first group patient receive study vaccine transplant . If find safe second group receive single study vaccine prior transplant . - Prior autologous stem cell transplant , harvest stem cell participant blood use transplant later . G-CSF give daily injection begin day chemotherapy GM-CSF injection start seven day chemotherapy . These injection continue stem cell collect . Approximately 10 day chemotherapy , participant undergo leukapheresis procedure collect stem cell . - Within week successful stem cell collection , participant admit hospital high dose chemotherapy autologous stem cell transplantation .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Patients multiple myeloma potential candidate high dose chemotherapy Measurable disease define history elevate M component plasma , urine , free kappa/lambda light chain serum 18 year age old ECOG Performance Status 01 great nine week life expectancy Patients &gt; 20 % bone marrow involvement plasmacytoma amenable resection local anesthesia Negative pregnancy test , adequate contraception method DLCO ( adjust ) &gt; 50 % Cardiac Ejection Fraction &gt; 45 % Laboratory value within range outline protocol History clinically significant venous thromboembolism Clinically significant autoimmune disease HIV positive Serious intercurrent illness infection require IV antibiotic , significant cardiac disease characterize significant arrhythmia , ischemic coronary disease congestive heart failure Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>DC/tumor cell fusion</keyword>
	<keyword>GM-CSF</keyword>
	<keyword>high dose chemotherapy</keyword>
</DOC>